Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2018

Shelley Wood

October 02, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

Case #8: A Case of Asymptomatic Leaflet Thrombosis: Management Strategies

Presenter: Philippe Genereux, Josep Rodés-Cabau, Suzanne V. Arnold, Wayne B. Batchelor, Pablo Lamelas, Tullio Palmerini, Shigeru Saito, Tobias Tichelbäcker

September 23, 2018

Presentation TCT 2018

Case #4: Clinically Significant TAVR Leaflet Thrombosis

Presenter: Samir R. Kapadia, Bernard Prendergast, Eric Eeckhout, Ganesh Manoharan, John C. Messenger, Bernhard Reimers, Paul Sorajja, Eric Vang

September 23, 2018

Presentation TCT 2018

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

Presenter: Michael J. Mack, Bernard Prendergast, George D. Dangas

September 22, 2018

Presentation TCT 2018

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

Presenter: Michael J. Mack, Bernard Prendergast, Davide Capodanno

September 22, 2018

Presentation TCT 2018

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Presenter: Michael J. Mack, Bernard Prendergast, Lars Sondergaard

September 22, 2018

Presentation TCT 2018

To Split or Not to Split: The Role of BASILICA to Reduce the Risk of Coronary Obstruction During ViV (and other TAVR) Procedures

Presenter: Michael J. Mack, Bernard Prendergast, Adam B. Greenbaum

September 22, 2018

Presentation TCT 2018

To Crack or Not to Crack: The Role of Fracturing Bioprosthetic Valves During ViV Procedures

Presenter: Michael J. Mack, Bernard Prendergast, Adnan K. Chhatriwalla

September 22, 2018

Presentation TCT 2018

How to Screen for Risk of Coronary Obstruction Risk on CT Prior to Aortic Valve-in-Valve Procedures

Presenter: Michael J. Mack, Bernard Prendergast, Philipp Blanke

September 22, 2018

Presentation TCT 2018

Clinical Lessons from the Global Aortic VIVID Registry Optimizing Procedural Outcomes

Presenter: Michael J. Mack, Bernard Prendergast, John G. Webb

September 22, 2018

Presentation The Structural Heart Disease Summit 2018

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

Presenter: Michael J. Mack, Raj Makkar

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

Presenter: Michael J. Mack, Raj Makkar, Maria Alu, MS

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Presenter: Michael J. Mack, Raj Makkar, Lars Sondergaard

June 22, 2018

Presentation The Structural Heart Disease Summit 2018

Recurrent Leaflet Thrombosis After Sapien 3 Valve-in-Valve TAVR

Presenter: Howard C. Herrmann, Fabian Nietlispach, Hasan Ahmad, MD

June 21, 2018

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Conference News EuroPCR 2018

Pace Quickens for Mitral Device Innovation for Repair, Replacement

Yael L. Maxwell

May 24, 2018

News Conference News CRT 2018

Ticagrelor: Better Platelet Blockade Post-TAVR?

Michael O'Riordan

March 07, 2018

News Conference News CRT 2018

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Michael O'Riordan

March 05, 2018

News Daily News

Structural Valve Degeneration: VIVID Group Proposes New, Graduated Definition

Michael O'Riordan

January 26, 2018

Advertisement

TCTMD’s Top 10 Most Popular Stories for September 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Case #8: A Case of Asymptomatic Leaflet Thrombosis: Management Strategies

Case #4: Clinically Significant TAVR Leaflet Thrombosis

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

To Split or Not to Split: The Role of BASILICA to Reduce the Risk of Coronary Obstruction During ViV (and other TAVR) Procedures

To Crack or Not to Crack: The Role of Fracturing Bioprosthetic Valves During ViV Procedures

How to Screen for Risk of Coronary Obstruction Risk on CT Prior to Aortic Valve-in-Valve Procedures

Clinical Lessons from the Global Aortic VIVID Registry Optimizing Procedural Outcomes

Should We Anticoagulate All Bioprosthetic Aortic Valves? Rationale, Ongoing Studies, and Recent Trends

New Guidelines and Classification of Bioprosthetic Valve Dysfunction and Failure: Implications and Thoughts on TAVR Durability

The Spectrum of Leaflet Thrombosis in Bioprosthetic Aortic Valves - Prevalence, Clinical Consequences, and Practical Management Strategies

Recurrent Leaflet Thrombosis After Sapien 3 Valve-in-Valve TAVR

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Pace Quickens for Mitral Device Innovation for Repair, Replacement

Ticagrelor: Better Platelet Blockade Post-TAVR?

Early Low-Risk TAVR Data Reassure, but Durability Questions Remain

Structural Valve Degeneration: VIVID Group Proposes New, Graduated Definition

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content